


**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original). A compound of the Formula I



Formula I

wherein:

R1 is NHR10, (substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR10 or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl)NHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

Q is -S(O)<sub>2</sub>- or -C(O)-;


m is a number selected from 1 or 2;

R3 is substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group; and R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-

C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, optionally substituted aryl, optionally substituted -O-aryl, optionally substituted -N-aryl, optionally substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group; or

R<sub>3</sub> is optionally substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; and R<sub>9</sub> is aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, -O-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, -N-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, or -S-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group; or a pharmaceutically acceptable salt or solvate thereof.

Claim 2 (original). A compound according to claim 1 having Formula II



Formula II

wherein

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> and Q are as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof.

Claim 3 (currently amended). A compound according to claim 1 or 2 wherein R<sub>3</sub> is selected from substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; or a pharmaceutically acceptable salt or solvate thereof.

Claim 4 (original). A compound according to claim 3 wherein the substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is substituted by from one to three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl,

-OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt or solvate thereof.

Claim 5 (currently amended). A compound according to ~~any one of claims 1 to 4~~ claim 2 wherein R<sub>3</sub> is a substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or a substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:


the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the substituted aryl moiety is 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4,6-trifluorophenyl, 2,3,4-trifluorophenyl, 2,4,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,3,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-methylphenyl, 2,6-difluoro-3-methylphenyl, 3,6-difluoro-2-chlorophenyl, 2-fluoro-6-chlorophenyl, 2-fluoro-3-chlorophenyl, 2-fluoro-4-chlorophenyl, 2,6-difluoro-3-chlorophenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-6-trifluoromethylphenyl, 2-chloro-3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-methanesulphonylphenyl, or 2-methyl thiazolyl;



or a pharmaceutically acceptable salt or solvate thereof.

Claim 6 (original). A compound according to ~~any one of claims 1 to 5~~ claim 2 wherein R<sub>1</sub> is



or a pharmaceutically acceptable salt or solvate thereof.

Claim 7 (currently amended). A compound according to ~~any one of claims 1 to 5~~ claim 2 wherein R1 is selected from  $-\text{C}(\text{CH}_2\text{F})_2\text{NH}_2$ ,  $-\text{C}(\text{CH}_2\text{F})(\text{CH}_2\text{CH}_2\text{F})\text{NH}_2$ ,  $-\text{C}(\text{CF}_3)(\text{CH}_3)\text{NH}_2$ ,  $-\text{C}(\text{CH}_2\text{CH}_2\text{F})_2\text{NH}_2$ ,  $-\text{C}(\text{CH}_2\text{CH}_3)(\text{CH}_2\text{CF}_3)\text{NH}_2$ ,



or a pharmaceutically acceptable salt or solvate thereof.

Claim 8 (currently amended). A compound according to ~~any one of claims 1 to 7~~ claim 2 wherein R6 and R7 are each  $\text{C}_1\text{-C}_3$  alkyl or form a five or six membered carbocyclic ring; or R6 and R7 are independently  $\text{C}_1\text{-C}_6$ alkyl or  $\text{C}_2\text{-C}_6$ alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is  $\text{C}_1\text{-C}_6$ alkyl,  $\text{C}_2\text{-C}_6$ alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a  $\text{C}_3\text{-C}_8$ cycloalkyl group which is optionally partly unsaturated and which is substituted by one, two, or three halo atoms;  
or a pharmaceutically acceptable salt or solvate thereof.

Claim 9 (currently amended). A compound according to ~~any one of claims 1 to 8~~ claim 1 wherein R4 is hydrogen or methyl, or a pharmaceutically acceptable salt or solvate thereof.

Claim 10 (currently amended). A compound according to ~~any one of claims 1 to 9~~ claim 2 wherein R5 is hydrogen,  $\text{C}_1\text{-C}_6$ alkyl,  $\text{C}_1\text{-C}_6$ alkoxy,  $\text{C}_1\text{-C}_6$ alkyl which is substituted by hydroxy or  $\text{C}_1\text{-C}_6$ alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

Claim 11 (currently amended). A compound according to ~~any one of claims 1 to 10~~ claim 10 wherein R5 is hydrogen, methyl, ethyl, propyl or n-propyl, or a pharmaceutically acceptable salt or solvate thereof.

Claim 12 (currently amended). A compound according to ~~any one of claims 1 to 11~~ claim 2 wherein R8 is hydrogen,  $\text{C}_1\text{-C}_6$ alkyl,  $(\text{C}_1\text{-C}_6\text{alkyl})\text{C}_3\text{-C}_8$ cycloalkyl, benzyl, 1-

phenylethyl, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy, methoxy, CONH<sub>2</sub>, or CON(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

Claim 13 (currently amended). A compound according to ~~any one of claims 3 or 10 to~~ claim 12 wherein R<sub>8</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.


Claim 14 (currently amended). A compound according to ~~any one of claims 1 to 13~~ claim 2 wherein R<sub>9</sub> is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt or solvate thereof.

Claim 15 (original). A compound of according to claim 14 wherein R<sub>9</sub> is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, thiazolyl, pyridyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, oxazolyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl, 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt or solvate thereof.


Claim 16 (currently amended). A pharmaceutical formulation comprising one or more compounds according to ~~any one of claims 1 to 15~~ claim 1 or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable diluents or carriers therefor.

Claim 17 (original). A pharmaceutical formulation according to claim 16 wherein the formulation further comprises one or more growth hormone secretagogue compounds and/or a bone-antiresorptive agent.

Claim 18 (currently amended). A process for producing a compound of Formula I as defined in ~~any one of claims 1 to 15~~ claim 1 comprising coupling a compound of Formula XI or XIb




with a compound of formula XIII




wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in ~~any one of claims 1 to 15~~ claim 1.

Claim 19 (currently amended). A process for producing a compound of Formula I as defined in ~~any one of claims 1 to 15~~ claim 1 comprising deprotecting a compound of Formula




wherein R2, R3, R4, R5, R6, R7, R8, R9, m and Q are as defined in ~~any one of claims 1 to 12~~ claim 1, and PG is an amino protecting group.

Claim 20 (currently amended). A process for producing a compound of Formula I as defined in ~~any one of claims 1 to 15~~ claim 1 comprising coupling a compound of Formula



with a compound of formula XIV




wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in ~~any one of claims 1 to 15~~ claim 1.

Claims 21 and 22 (canceled).

Claim 23 (currently amended). A method ~~of using~~ comprising administering an effective amount of a compound of claim 1 to 2 or a pharmaceutically acceptable salt or solvate thereof for the treatment of a physiological condition which ~~may be~~ is modulated or ameliorated by an increase in endogenous growth hormone, ~~which method comprises administering to an animal in need of said treatment an effective amount of a compound of formula I.~~

Claim 24 (new). A compound having the formula



wherein:

X is O, Y is 4-Cl, Z is 2-F and R5 is Et;

or

X is O, Y is 4-Cl, Z is 3-F and R5 is Et;

or

X is O, Y is 4-Cl, Z is 4-F and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2,3-F<sub>2</sub> and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2,5-F<sub>2</sub> and R5 is Et;

or

X is CH<sub>2</sub>, Y is 4-Cl, Z is 2,6-F<sub>2</sub> and R<sub>5</sub> is Et;

or

X is O, Y is 4-Cl, Z is 2,6-F<sub>2</sub> and R<sub>5</sub> is Et;

or

X is CH<sub>2</sub>, Y is 4-Cl, Z is 3,5-F<sub>2</sub> and R<sub>5</sub> is Et;

or

X is O, Y is 4-Cl, Z is 2,4,6-F<sub>3</sub> and R<sub>5</sub> is Et;

or

X is O, Y is 4-Cl, Z is 2,3,5-F<sub>3</sub> and R<sub>5</sub> is Et;

or

X is O, Y is 4-Cl, Z is 2,6-Cl<sub>2</sub> and R<sub>5</sub> is Et;

or

X is O, Y is 4-Cl, Z is 2-F-6-Cl and R<sub>5</sub> is Et;

or

X is O, Y is 4-Cl, Z is 2-Cl-3,6-F<sub>2</sub> and R<sub>5</sub> is Et;

or

X is O, Y is 4-Cl, Z is 2-CN and R<sub>5</sub> is Et;

or a pharmaceutically acceptable salt or solvate thereof.

Claim 25 (new). A compound selected from the group consisting of 2-(R)-2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)- 3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; or a pharmaceutically acceptable salt or solvate thereof.